New Oral MS Drug Reduces Relapses

Oral Laquinimod reduced MS relapses by 23% in phase III trial as reported by Giancarlo Comi at the AAN meeting in Hawaii. Most importantly, Laquinimod reduced cerebral atrophy by 33%. The drugs novel mechanism of action addresses inflammatory activity and accumulation of irreversible tissue damage. Also importantly the side effect was low especially compared to fingolimod (Gilenya) released this past year. Teva produces Laquinimod